Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 323,978
  • Shares Outstanding, K 18,513
  • Annual Sales, $ 440 K
  • Annual Income, $ -35,130 K
  • EBIT $ -67 M
  • EBITDA $ -66 M
  • 60-Month Beta 0.88
  • Price/Sales 1,042.18
  • Price/Cash Flow N/A
  • Price/Book 3.41

Options Overview Details

View History
  • Implied Volatility 137.79% (+17.11%)
  • Historical Volatility 89.52%
  • IV Percentile 29%
  • IV Rank 22.35%
  • IV High 449.33% on 05/13/25
  • IV Low 48.13% on 09/04/25
  • Expected Move (DTE 18) 3.40 (19.43%)
  • Put/Call Vol Ratio 0.48
  • Today's Volume 185
  • Volume Avg (30-Day) 860
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 18,464
  • Open Int (30-Day) 12,646
  • Expected Range 14.10 to 20.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.54
  • Number of Estimates 5
  • High Estimate -1.29
  • Low Estimate -1.93
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.04 +16.95%
on 02/05/26
17.87 -14.66%
on 02/26/26
-0.40 (-2.56%)
since 02/02/26
3-Month
13.04 +16.95%
on 02/05/26
20.72 -26.40%
on 12/11/25
-0.62 (-3.91%)
since 12/02/25
52-Week
3.39 +349.85%
on 05/14/25
20.72 -26.40%
on 12/11/25
+7.94 (+108.62%)
since 02/28/25

Most Recent Stories

More News
Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 15.25 (-12.86%)
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 15.25 (-12.86%)
Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 15.25 (-12.86%)
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 15.25 (-12.86%)
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership...

AVTX : 15.25 (-12.86%)
Avalo Therapeutics to Participate in Upcoming Investor Conferences

WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 15.25 (-12.86%)
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 15.25 (-12.86%)
3 Biotech Stocks That Could More Than Triple if Their Trials Succeed

While the risks remain significant with biotech stocks, the potential rewards could be equally compelling.

ATXS : 12.58 (+0.64%)
AVTX : 15.25 (-12.86%)
GOSS : 0.4062 (-4.40%)
Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Avalo Therapeutics...

AVTX : 15.25 (-12.86%)
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 15.25 (-12.86%)

Business Summary

Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is...

See More

Key Turning Points

3rd Resistance Point 18.95
2nd Resistance Point 18.29
1st Resistance Point 17.90
Last Price 15.25
1st Support Level 16.85
2nd Support Level 16.19
3rd Support Level 15.80

See More

52-Week High 20.72
Last Price 15.25
Fibonacci 61.8% 14.10
Fibonacci 50% 12.05
Fibonacci 38.2% 10.01
52-Week Low 3.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar